ArticleResearch in pharmaceutical sciences2021
Preparation and characterization of Eudragit L 100-55/chitosan enteric nanoparticles containing omeprazole using general factorial design:
Article in Research in pharmaceutical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Fabrication of pantoprazole-loaded microsphere clusters with enteric and mucoadhesive properties for enhanced ulcer targeting.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Developing and Evaluating Stable Microemulsion Systems for Potential Intranasal and Transdermal Application of Omeprazole.AAPS PharmSciTech · 2026Article
- Design and PreliminaryCurrent pharmaceutical biotechnology · 2026Article
- Preparation and evaluation of oral enteric sustained-release liquid formulations of aspirin.Nanomedicine (London, England) · 2025Article
- Article
- The Study of Amorphous Kaempferol Dispersions Involving FT-IR Spectroscopy.International journal of molecular sciences · 2023Article
- Review
- Development and evaluation of polycaprolactone-based electrospun nanofibers containing timolol maleate as a sustained-release device for treatment of glaucoma:Research in pharmaceutical sciences · 2022Article
- Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives.Pharmaceutics · 2022Review
- Somatostatin plus Gastroscopic Administration of Omeprazole for the Treatment of Acute Upper Gastrointestinal Bleeding: An Exploration of a Promising Alternative.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeOmeprazole (OMP) is broadly used for the treatment of gastroesophageal reflux and other acid-related diseases. The current study aimed to prepare enteric-coated nanoparticles containing OMP to achieve a stable powder formulation easily prescribed in children. EXPERIMENTAL APPROACH: The nanoparticles were formed by complex coacervation method using chitosan (CTS) and Eudragit L100/55 (EU) and the impact of various formulation variables (the concentrations of EU solution and its volume ratio to CTS solution) were assessed using 3 FINDINGS/
resultsThe highest desirability value was for formulation F5 (containing EU concentration 4 mg/mL and EU/CTS volume ratio 2:1). PS, ZP, EE, and DL of the optimized OMP-loaded nanoparticles were confirmed 810 ± 14 nm, -38.2 ± 1.8 mV, 83.1± 4.2%, and 13.1± 1.5%, respectively. CONCLUSION AND IMPLICATION: Our results indicated that the enteric EU/CTS nanoparticles were successfully prepared
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.